On October 30, 2017 Cerus Corp. announced that it has entered into a two-year supply contract with Centro de Transfusion de la Comunidad de Madrid (CTCM) for the INTERCEPT Blood System for platelets.
The French Ministry of Health decided late 2016 that platelet pathogen inactivation should be deployed throughout the entire French territory for the control of bacterial infections transmitted by transfusion, following the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM).
In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.
The Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa.
Cerus has entered an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support Cerus’ clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, such as the funding of studies necessary to support an FDA submission and to accelerate commercial scale.
At Cerus, we work to enhance and save lives. We usually do this by advancing the safety, efficacy and availability of blood, but this time I’d like to ask for your support to save and enhance life in a different way.